AHA names Atlantic Health’s Gragnolati as chair-elect designate

Brian Gragnolati, president and CEO of Morristown, New Jersey-based Atlantic Health System, has been selected to become chairman of the American Hospital Association’s board of trustees beginning in 2019.

He first joined the AHA board in 2015, the same year he took over at the six-hospital Atlantic Health System. Previous roles include senior vice president in the community division at John Hopkins Medicine, as well as president/CEO roles at Suburban Hospital in Bethesda, Maryland, and WellSpan Health in York, Pennsylvania.

“More than ever, now is a critically important and exciting time to be a leader in the health care field as we drive the transformation of care in America,” Gragnolati said in a statement. “I look forward to working with the AHA’s members across the country in support of the association’s mission to advance the health of individuals and communities.”

According to the AHA, Gragnolati began his career as an emergency medical technician. He earned a B.S. in Health Systems Analysis from the University of Connecticut and an MBA from Western New England College. He is also a fellow of the American College of Healthcare Executives.

The chair of the AHA board is the highest elected office at the association. Gragnaloti’s 2019 tenure will follow that of current chair Eugene Woods, president and CEO of Carolinas Healthcare System in Charlotte, and chair-elect Nancy Howell Agee, president and CEO of Carilion Clinic in Roanoke, Va.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.